Gilead Sciences & Merck press release
FOSTER CITY, Calif. & RAHWAY, N.J., July 21, 2026 — Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (AIDS 2026). The primary endpoint results at Week 48 showed that the investigational once-weekly oral single-tablet HIV treatment regimen of islatravir 2 mg/lenacapavir 300 mg (ISL/LEN) was effective in adults living with HIV who were virologically suppressed and switched from global guideline-recommended BIKTARVY® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) (ISLEND-1) or other standard of care oral daily antiretroviral regimens (ISLEND-2). The safety profile of ISL/LEN was generally similar to the comparator regimens studied in the ISLEND trials, and no new safety concerns were identified. Results of both trials will be presented during late-breaking sessions at AIDS 2026 on Wednesday, July 29 and featured in the AIDS 2026 press program on Tuesday, July 21. These data will form the basis of regulatory submissions.
Read the full press release here.
SEE ALSO:
- Gilead to present new HIV research at AIDS 2026 across prevention, treatment and cure
- Merck to present new data on daily, weekly, and monthly options across its HIV treatment and prevention pipeline at AIDS 2026
Source : Gilead Sciences, Inc.
Related HIV and Co-Infections News
-
[AIDS 2026] IAS: Data revealing the impact of PEPFAR disruptions and advances in long-acting HIV prevention and treatment announced ahead of AIDS 2026
-
ACTG announces behavioral health and implementation study to optimize long-acting HIV treatment among people who have struggled to maintain HIV suppression
-
Medicines Patent Pool: Accelerating access to long-acting HIV medicines: A new roadmap for global health
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.